- $19.42m
- $17.51m
- $2.69m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 76.41 | ||
| Price to Tang. Book | 121.23 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.62 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -820.21% | ||
| Return on Equity | n/a | ||
| Operating Margin | -259.62% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.93 | 2.72 | 2.68 | 2.46 | 2.69 | 4,612.9 | 11,000 | 8.61% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Neuraxis, Inc. is a medical technology company. The Company is focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. It focuses on advancing science and leveraging evidence-based medicine to drive the adoption of its IB-Stim therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is a food and drug administration (FDA) cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years old. The Company’s second product, the Rectal Expulsion Device (RED), is indicated to evaluate the neuromuscular function of a patient’s ability to expel its contents from the rectum and as a qualitative test for rectal hypersensitivity. RED (K242304, 2024) helps identify patients with rectal hypersensitivity who experience a desire or urge defecating at lower volumes of distension.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- June 23rd, 2022
- Public Since
- August 9th, 2023
- No. of Shareholders
- 682
- No. of Employees
- 21
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NYSE MKT- Shares in Issue
- 7,832,326
- Address
- 11611 N. Meridian St, Suite 330, CARMEL, 46032
- Web
- https://neuraxis.com/
- Phone
- +1 8126890791
- Auditors
- ROSENBERG RICH BAKER BERMAN, P.A.
Similar to NRXS
Acme United
NYSE MKT
Alpha Pro Tech
NYSE MKT
Catheter Precision
NYSE MKT
Electromed
NYSE MKT
Infusystem Holdings
NYSE MKT
FAQ
As of Today at 22:14 UTC, shares in Neuraxis are trading at $2.48. This share price information is delayed by 15 minutes.
Shares in Neuraxis last closed at $2.48 and the price had moved by -6.77% over the past 365 days. In terms of relative price strength the Neuraxis share price has underperformed the S&P500 Index by -17.53% over the past year.
The overall consensus recommendation for Neuraxis is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreNeuraxis does not currently pay a dividend.
Neuraxis does not currently pay a dividend.
Neuraxis does not currently pay a dividend.
To buy shares in Neuraxis you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.48, shares in Neuraxis had a market capitalisation of $19.42m.
Here are the trading details for Neuraxis:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: NRXS
Based on an overall assessment of its quality, value and momentum Neuraxis is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Neuraxis is $6.25. That is 152.02% above the last closing price of $2.48.
Analysts covering Neuraxis currently have a consensus Earnings Per Share (EPS) forecast of -$0.98 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neuraxis. Over the past six months, its share price has underperformed the S&P500 Index by -2.34%.
As of the last closing price of $2.48, shares in Neuraxis were trading -3.21% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Neuraxis PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Neuraxis' directors